SAP ECC Oracle EPM Pharma / Life Sciences

Cross-Vendor TPS: £2.4M Annual Saving on SAP & Oracle — European Pharmaceutical Group

How a 9,000-employee European pharmaceutical manufacturer consolidated SAP ECC and Oracle Hyperion EPM onto independent third-party support — achieving a 65% combined saving with full GxP validation compatibility confirmed before go-live.

£2.4M
Annual saving
65%
Combined saving rate
2
Vendor contracts replaced
GxP
Validated — FDA + EU GMP
6 wk
Time to full TPS onboarding

Background: Two Vendors, Two Separate Escalation Pressures

The client is a mid-sized European pharmaceutical group with manufacturing sites in Germany, the Netherlands, and Ireland, producing branded prescription medicines and contract manufacturing services for global pharma majors. With approximately 9,000 employees and annual revenue of €2.3 billion, the group runs a mature SAP ECC landscape as its core ERP and Oracle Hyperion EPM as its financial consolidation and planning layer.

In 2024, both vendors escalated simultaneously — and for different commercial reasons. SAP issued a formal S/4HANA transition assessment, positioning SAP ECC mainstream maintenance end (January 2027 under standard terms) as a hard deadline requiring immediate project initiation. Oracle communicated that Hyperion EPM System 11.1.2.4 would enter the final phase of Sustaining Engineering at end of 2026, with a strong push toward Oracle EPM Cloud as the "only supported path forward."

The group's Group CIO and CFO faced a potential combined vendor migration budget of £18M–£32M over three to five years, with no certainty on business benefits and significant disruption risk to GxP-validated financial processes. An independent assessment was commissioned to evaluate the third-party support alternative.

The GxP Question: Addressing the Primary Concern

For pharmaceutical manufacturers operating under FDA 21 CFR Part 11 and EU GMP Annex 11, the question of whether a change to the software support model constitutes a "change" for CSV (Computer System Validation) purposes is critical. A CSV-triggering change would require revalidation of validated systems — a process that, for a system of SAP ECC's scope, could cost £500K–£2M and consume 6–12 months of regulatory affairs resource.

GxP Validation Determination — TPS Is Administrative, Not System Change

Third-party support involves no modification to the validated software itself. The software version, configuration, data, and functional specification remain unchanged. Regulatory guidance under GAMP 5 Category 3 and FDA 21 CFR Part 11 consistently classifies a change to the support provider — with no change to the software — as an administrative change under Configuration Management, not a CSV-triggering technical change. The group's internal validation team, supported by an independent regulatory affairs consultant, confirmed this determination in writing before TPS transition.

The GxP determination was completed in four weeks. The documented rationale — software version unchanged, no functional modification, support provider change classified as administrative — was reviewed by the group's Qualified Person (QP) and confirmed as compliant. The assessment was filed in the system validation file for SAP ECC, Oracle Hyperion Planning, and Oracle HFM respectively.

SAP ECC Estate — What Was Covered

The group's SAP landscape comprised SAP ECC 6.0 (EHP 8) across three production systems covering manufacturing (PP-PI, QM, WM), supply chain (MM, WM, SD, GTS), and finance (FI-CO, CO-PA). Critical elements of the SAP estate with pharmaceutical sector significance:

Oracle Hyperion EPM Estate — What Was Covered

The Oracle EPM estate provided the group's financial consolidation layer: legal entity consolidation under IFRS, currency translation, intercompany elimination across 14 legal entities, and statutory reporting formats for Germany, Netherlands, and Ireland. The estate comprised:

The Vendor Saving Breakdown

SAP ECC + BW TPS Saving

£1,544,000

Annual saving vs. SAP SnS (65%)

  • SAP ECC 6.0 EHP 8 (core ERP)
  • SAP QM / PP-PI / WM / GTS
  • SAP BW 7.5 on HANA
  • Full ABAP custom code coverage

Oracle Hyperion EPM TPS Saving

£856,000

Annual saving vs. Oracle SnS (64%)

  • Hyperion Financial Management 11.1.2.4
  • Hyperion Planning 11.1.2.4
  • Oracle FDMEE / FDM
  • Oracle Essbase (ASO)

Combined Financial Impact

MetricSAPOracle EPMCombined
Vendor SnS (annual)£2,374,000£1,338,000£3,712,000
TPS cost (annual)£830,000£482,000£1,312,000
Annual saving£1,544,000£856,000£2,400,000
Saving %65%64%65%
3-year saving£4,632,000£2,568,000£7,200,000

The Migration Economics That Made TPS Obvious

The group's independent assessment of the vendor migration alternative produced the following cost projection:

"We modelled SAP and Oracle migration on every reasonable set of assumptions. Every model produced the same conclusion: if there is no strategic imperative to migrate within five years — and there is not — third-party support is the only rational commercial decision."

— Group CIO, European Pharmaceutical Group

Implementation Timeline

1

Week 1–2: GxP determination and validation assessment

Internal validation team and external regulatory affairs consultant confirmed TPS classified as administrative change. GxP determination documented and filed. Approved by QP.

2

Week 2–3: Vendor contracts review and cancellation notices

SAP Enterprise Agreement — 90-day cancellation notice served. Oracle SnS — 30-day cancellation notice served. Both served in the same week to align transition dates.

3

Week 3–5: TPS provider technical onboarding

SAP estate discovery — system landscape, transport routes, custom ABAP inventory, QM/PP-PI integration points. Oracle EPM discovery — HFM metadata, Planning application structure, FDMEE integration, Essbase outline. Monitoring agents deployed across all systems.

4

Week 5–6: SLA configuration and hypercare period

P1/P2/P3 SLA parameters confirmed. 24/7 coverage confirmed for SAP QM and HFM (period-end criticality). Hypercare period — daily check-ins with TPS support team for first 4 weeks post-go-live.

5

Month 3: First annual period-end under TPS

First full-year financial close under TPS — HFM consolidation, intercompany elimination, IFRS statutory reporting — completed without incident. SAP QM batch release cycle (quarterly product review) completed without incident.

First-Year Outcomes

After 12 months under combined SAP and Oracle TPS, the group reported the following outcomes:

Running SAP and Oracle in a Regulated Environment?

We've helped pharmaceutical groups across Europe confirm GxP compatibility, model combined TPS saving, and transition both vendor estates within 6 weeks. Get your independent assessment.

Request Your Pharma TPS Assessment

Related Resources

For detailed coverage of the technical and regulatory considerations behind this case study, see the following GoVendorFree resources:

Est. 2016
500+ clients
50–90% savings
40+ countries
98.7% retention
15-min response SLA

Your Turn

Find Out What Your Organisation Can Save

Results like these aren't outliers — they're what happens when you stop paying vendor tax. Our free assessment shows your exact savings potential in 48 hours.

Get My Free Assessment → See More Case Studies

Est. 2016 · 500+ clients · 40+ countries · 15-min response